MedTrace Logo

Sorafenib Combined With Aspirin to Prevent the Recurrence in High-risk Patients With Hepatocellular Carcinoma

NCT02748304 · Status: TERMINATED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 52

Last updated 2019-02-15

No results posted yet for this study

Summary

The purpose of the study is to observe the effect of sorafenib combined with aspirin in preventing the recurrence in high-risk patients with hepatocellular carcinoma.

Conditions

Interventions

OTHER

control

just follow up

DRUG

sorafenib

sorafenib 400mg bid po

DRUG

aspirin

aspirin 100mg qd po

Sponsors & Collaborators

  • Fudan University

    lead OTHER

Principal Investigators

  • Lunxiu Qin, MD · Department of general surgery, Huashan hospital, Fudan University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-04-30
Primary Completion
2019-02-11
Completion
2019-02-11

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02748304 on ClinicalTrials.gov